Crystal structure of Mycobacterium tuberculosis mycothione reductase in complex with a specific inhibitor reveals competition with NADP (H) binding
FEBS Letters · 2026-08 · 600 (15) · 2143-2153
DOI: 10.1002/1873-3468.70336 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Letters, online erschienen am 23.05.2026. Verfasst von Lauren Oorts und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, …. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, NADP, Enzyme Inhibitors, Bacterial Proteins. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fonds Wetenschappelijk Onderzoek, Innovative Health Initiative.
Abstract (Originalsprache)
Tuberculosis (TB) remains a major health threat, while the increasing occurrence of drug‐resistant strains underscores the need for new antitubercular drugs. A promising strategy to combat TB is based on disrupting the mycobacterial redox homeostasis by inhibiting an NADPH‐dependent oxidoreductase, mycothione reductase (Mtr). Using high‐throughput screening, we recently identified potent and selective Mtr inhibitors. Here we report high‐resolution X‐ray structures of Mtr from Mycobacterium tuberculosis and Mycobacterium xenopi, including the M. tuberculosis enzyme complexed with a novel inhibitor, Respiri‐1093. Our findings demonstrate that Respiri‐1093 competes with the NADP(H) binding rather than mycothione binding. Analysis of the binding site explains the observed selectivity of the inhibitor towards the M. tuberculosis enzyme. These results provide a structural basis for rational drug design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Belgium.
- Biocrystallography, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- Laboratory of Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Belgium.
- Janssen Pharmaceutica NV, Beerse, Belgium.
ORCID-Profile: Sergei V Strelkov
Förderung
- Fonds Wetenschappelijk Onderzoek
- Innovative Health Initiative
Zitieren
APA
Oorts, L., Osipov, E. M., Beelen, S., Smiejkowska, N., Van Calster, K., Lamprecht, D., Temmerman, K., Van Aerschot, A., Cappoen, D., Cos, P., & Strelkov, S. V. (2026). Crystal structure of Mycobacterium tuberculosis mycothione reductase in complex with a specific inhibitor reveals competition with NADP (H) binding. FEBS Letters, 600(15), 2143-2153. https://doi.org/10.1002/1873-3468.70336
Vancouver
Oorts L, Osipov EM, Beelen S, Smiejkowska N, Van Calster K, Lamprecht D, et al. Crystal structure of Mycobacterium tuberculosis mycothione reductase in complex with a specific inhibitor reveals competition with NADP (H) binding. FEBS Letters. 2026;600(15):2143-2153. doi:10.1002/1873-3468.70336
BibTeX
@article{Oorts2026,
author = {Oorts, Lauren and Osipov, Evgenii M and Beelen, Steven and Smiejkowska, Natalia and Van Calster, Kevin and Lamprecht, Dirk and Temmerman, Koen and Van Aerschot, Arthur and Cappoen, Davie and Cos, Paul and Strelkov, Sergei V},
title = {Crystal structure of Mycobacterium tuberculosis mycothione reductase in complex with a specific inhibitor reveals competition with NADP (H) binding},
journal = {FEBS Letters},
year = {2026},
volume = {600},
number = {15},
pages = {2143--2153},
doi = {10.1002/1873-3468.70336}
}
EUVIMED